Mergers & Acquisitions ·
Theravance Biopharma completed its merger with Zymeworks on September 23, 2026
TBPHTheravance Biopharma, Inc.
Theravance Biopharma completed its merger with Zymeworks on September 23, 2026. Each outstanding ordinary share was canceled and converted into $17.00 in cash plus one contingent value right (CVR). CVRs entitle holders to a pro rata share of 80% of net license proceeds for ampreloxetine within ten years, a $0.93 per-CVR milestone payment upon first commercial sale in major markets, and a 10% royalty on net sales. The company's shares were delisted from Nasdaq, and it became a wholly owned subsidiary of Zymeworks. All directors resigned, and new directors were appointed. Theravance Biopharma operates in the biotechnology industry, focusing on drug discovery and development.